A study reported resistance mechanisms in NSCLC with MET amplification and ROS1 rearrangement treated with the ROS1/MET dual inhibition strategy of lorlatinib plus crizotinib, where the subsequent emergence of MET-targeting resistant mutations and a loss of MET amplification highlighted tumor cell resistance to sequential targeted therapy [121]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.